Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147515 | 0.90 | RET (0.42) | RETALDH1A1TSHRMAPK1CTSS | |
| SCHEMBL20069721 | 0.86 | RET (0.42) | RETALDH1A1TSHRCTSSSMN1; SMN2 | |
| SCHEMBL20148040 | 0.80 | RET (0.41) | RETALDH1A1SMN1; SMN2 | |
| SCHEMBL20206053 | 0.80 | RET (0.41) | RETALDH1A1TSHRSMN1; SMN2HRH3 | |
| SCHEMBL25503510 | 0.78 | RET (0.45) | RETALDH1A1SMN1; SMN2 | |
| SCHEMBL20147512 | 0.76 | RET (0.42) | RET | |
| SCHEMBL20147519 | 0.73 | RET (0.40) | RETALDH1A1TSHRSMN1; SMN2HRH3 | |
| SCHEMBL20206054 | 0.73 | — | — | |
| SCHEMBL20147488 | 0.72 | RET (0.42) | RETALDH1A1CTSSSMN1; SMN2HRH3 | |
| SCHEMBL20069726 | 0.72 | RET (0.42) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885ALDH1A1 2547/4885TSHR 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.